Circulating Tumor DNA in Breast Cancer: A Liquid Biopsy Revolution for Non-Invasive Genomic Profiling and Clinical Decision-Making
Emmanuel Ifeanyi Obeagu, Chukwuma J Okafor · 2026
Read Circulating Tumor DNA in Breast Cancer: A Liquid Biopsy Revolution for Non-Invasive Genomic Profiling and Clinical Decision-Making by Emmanuel Ifeanyi Obeagu, Chukwuma J Okafor (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13542536.txt.
Description
Emmanuel Obeagu and Chukwuma Okafor review blood-based cancer DNA testing in breast cancer care, in a 2026 paper. Breast cancer is the most diagnosed cancer in women worldwide. Tissue biopsy, the standard for molecular profiling, is invasive and cannot easily track how a tumor changes over time or across sites.
Tumors shed fragments of DNA into the blood. Sensitive platforms can read mutations in those fragments, in genes tied to drug choice and resistance. The strongest current uses are spotting leftover disease after treatment, watching response, catching resistance early, and guiding targeted therapy in advanced cases. Screening healthy people and very early detection remain unproven. Low DNA amounts in early disease, uneven test standards, and cost still block routine use. The authors call for large prospective trials and shared protocols.
Catalog record
| CREATOR | Emmanuel Ifeanyi Obeagu, Chukwuma J Okafor |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |